Literature DB >> 7001832

Insulin secretory reserve in insulin dependent patients at time of diagnosis and the first 180 days of insulin treatment.

S Madsbad, T Krarup, L Regeur, O K Faber, C Binder.   

Abstract

Eleven newly diagnosed insulin dependent patients were studied before and during the first 16 h after start of insulin treatment. All the patients were found to have significant amounts of C-peptide in plasma indicating residual insulin secretion. The fall in blood glucose after start of insulin therapy was followed by a parallel decrease in C-peptide (R = 0.99, P < 0.01) suggesting that the beta-cells may respond to variation in blood glucose. Eight of the patients were studied 1, 4, 7, 14, 90 and 180 days after start of insulin therapy. During the first 90 days of treatment an increasing maximal C-peptide concentration was found after a standard breakfast test meal. Two thirds of this improvement i beta-cell function was found after the initial 14 days with an average increase in maximal C-peptide of 260 per cent. The sensitivity to glucose improved.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7001832     DOI: 10.1530/acta.0.0950359

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  12 in total

1.  Prevalence of residual B cell function and its metabolic consequences in Type 1 (insulin-dependent) diabetes.

Authors:  S Madsbad
Journal:  Diabetologia       Date:  1983-03       Impact factor: 10.122

2.  Factors affecting and patterns of residual insulin secretion during the first year of type 1 (insulin-dependent) diabetes mellitus in children.

Authors:  E B Sochett; D Daneman; C Clarson; R M Ehrlich
Journal:  Diabetologia       Date:  1987-07       Impact factor: 10.122

Review 3.  Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes.

Authors:  Jeff Unger
Journal:  Curr Diab Rep       Date:  2013-10       Impact factor: 4.810

4.  Prevalence of residual B-cell function related to age at onset and genetic profile in newly diagnosed type I diabetics.

Authors:  C Giordano; A Galluzzo; F Pantò; C Caruso; G Bompiani
Journal:  Acta Diabetol Lat       Date:  1987 Oct-Dec

5.  Deletion of GαZ protein protects against diet-induced glucose intolerance via expansion of β-cell mass.

Authors:  Michelle E Kimple; Jennifer B Moss; Harpreet K Brar; Taylor C Rosa; Nathan A Truchan; Renee L Pasker; Christopher B Newgard; Patrick J Casey
Journal:  J Biol Chem       Date:  2012-03-28       Impact factor: 5.157

Review 6.  Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus.

Authors:  Claire M Issa; Sami T Azar
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

7.  Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.

Authors:  K C Herold; S E Gitelman; S M Willi; P A Gottlieb; F Waldron-Lynch; L Devine; J Sherr; S M Rosenthal; S Adi; M Y Jalaludin; A W Michels; J Dziura; J A Bluestone
Journal:  Diabetologia       Date:  2012-10-21       Impact factor: 10.122

8.  Synergy Between Gαz Deficiency and GLP-1 Analog Treatment in Preserving Functional β-Cell Mass in Experimental Diabetes.

Authors:  Allison L Brill; Jaclyn A Wisinski; Mark T Cadena; Mary F Thompson; Rachel J Fenske; Harpreet K Brar; Michael D Schaid; Renee L Pasker; Michelle E Kimple
Journal:  Mol Endocrinol       Date:  2016-04-06

9.  Beta-cell function recovery is not the only factor responsible for remission in type I diabetics: evaluation of C-peptide secretion in diabetic children after first metabolic recompensation and at partial remission phase.

Authors:  E Schober; G Schernthaner; H Frisch; M Fink
Journal:  J Endocrinol Invest       Date:  1984-10       Impact factor: 4.256

10.  Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay.

Authors:  Limei Wang; Nicholas Fraser Lovejoy; Denise L Faustman
Journal:  Diabetes Care       Date:  2012-03       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.